| Literature DB >> 19573811 |
Lauren T McGillicuddy1, Jody A Fromm, Pablo E Hollstein, Sara Kubek, Rameen Beroukhim, Thomas De Raedt, Bryan W Johnson, Sybil M G Williams, Phioanh Nghiemphu, Linda M Liau, Tim F Cloughesy, Paul S Mischel, Annabel Parret, Jeanette Seiler, Gerd Moldenhauer, Klaus Scheffzek, Anat O Stemmer-Rachamimov, Charles L Sawyers, Cameron Brennan, Ludwine Messiaen, Ingo K Mellinghoff, Karen Cichowski.
Abstract
Loss-of-function mutations in the NF1 tumor suppressor result in deregulated Ras signaling and drive tumorigenesis in the familial cancer syndrome neurofibromatosis type I. However, the extent to which NF1 inactivation promotes sporadic tumorigenesis is unknown. Here we report that NF1 is inactivated in sporadic gliomas via two mechanisms: excessive proteasomal degradation and genetic loss. NF1 protein destabilization is triggered by the hyperactivation of protein kinase C (PKC) and confers sensitivity to PKC inhibitors. However, complete genetic loss, which only occurs when p53 is inactivated, mediates sensitivity to mTOR inhibitors. These studies reveal an expanding role for NF1 inactivation in sporadic gliomagenesis and illustrate how different mechanisms of inactivation are utilized in genetically distinct tumors, which consequently impacts therapeutic sensitivity.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19573811 PMCID: PMC2897249 DOI: 10.1016/j.ccr.2009.05.009
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743